Business Wire

Plasma One Launches to Herald a New Era of Stablecoin Banking

19.6.2026 14:29:00 CEST | Business Wire | Press Release

Share

Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning.

Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees.

Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure.

Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins instantly, cheaply and reliably at global scale. By owning the infrastructure beneath the product, Plasma is building more than an app. It is creating a vertically integrated financial stack for stablecoins, spanning blockchain infrastructure, liquidity, payments, licensing and consumer distribution.

Paul Faecks, Founder and Chief Executive Officer at Plasma, said: “Stablecoins will not become part of everyday banking through another app sitting on top of someone else’s rails. They need a product that brings the entire experience together. That’s what Plasma One is built to do. By combining the network, payments stack, and user experience into a single platform, Plasma One makes it possible to spend, send, save, and earn with digital dollars as seamlessly and reliably as people use money today.”

From launch, Plasma One delivers the full feature set users expect from a modern neobank:

  • Deposit - Add stablecoins directly from your wallet, or fund your account in USD, EUR, GBP, MXN and BRL through dedicated virtual accounts connected to local payment rails, including SEPA, Faster Payments and ACH.
  • Spend - Pay with your Plasma One Visa card across 180+ countries. In addition to up to 4% cashback on qualified purchases, Plasma One rewards AI power users with dedicated benefits: the Core tier offers 5% cashback on eligible AI spend plus a year of ChatGPT Go, while the Platinum tier offers 10% cashback on eligible AI spend, along with an annual subscription to ChatGPT Go and Claude Pro.
  • Send - Move money across borders in seconds, with unlimited free transfers settled on the Plasma Network.
  • Earn - Put idle balances to work with seamless access to competitive on-chain yields.

Zaheer Ebtikar, Chief Strategy Officer at Plasma, said:“Global stablecoin supply has roughly doubled in the last two years, but supply isn’t adoption. Adoption is when stablecoins become simple enough for anyone to use every day. With Plasma One, users can onboard in minutes, add digital dollars, spend with a card, send money globally, and put balances to work from one product. We are taking the efficiency of blockchain technology and combining it with the familiarity of money, creating an experience that feels faster, more global and more useful than traditional finance. That is the standard stablecoins need to reach billions of people.”

Plasma One’s private beta has already amassed 5,000 weekly active users and today's launch is just the beginning - over the coming months, Plasma will add new capabilities for consumers and businesses alike as it continues building out the infrastructure to make stablecoin banking work at scale.

About Plasma

Plasma builds financial products for consumers and businesses using stablecoins instead of traditional banking rails. Plasma One, its first product, lets users send, spend, save, and earn with stablecoins. Everything runs on Plasma's own blockchain, built from the ground up for speed, reliability, and scale.

Disclaimer: Plasma is a financial technology company, not a regulated financial institution, bank, money services business or investment advisor. Plasma does not custody your assets. The stablecoin assets in your Plasma One account are owned and custodied by you. The value of any cryptocurrency, including stablecoin assets pegged to fiat currency, commodities, or any other asset, may go to zero. Stablecoin balances are not bank deposits.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260619440985/en/

Contacts

Media Contact: Kishan Naran - kishan.naran@wachsman.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Special Olympics Airlift Takes Flight Nationwide; Dove 1 Arrives at St. Paul Downtown Airport19.6.2026 17:09:00 CEST | Press Release

The 2026 Special Olympics Airlift officially took flight today as all participating Cessna, Beechcraft and Hawker aircraft, known as Doves, departed from airports across the country. Dove 1 for arrival day, a Cessna Citation Latitude generously operated by Prent Corporation, landed at St. Paul Downtown Airport (STP) carrying Special Olympic athletes and delegation members, signaling the start of Airlift arrivals for the Special Olympics USA Games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619085293/en/ Special Olympics Airlift takes flight nationwide; Dove 1 arrives at St. Paul Downtown Airport (Photo credit: Textron Aviation). The arrival signals the start of the world’s largest cumulative peacetime airlift spanning more than 40 years, a coordinated aviation effort organized by Textron Aviation, a Textron Inc. (NYSE: TXT) company, that transports hundreds of Special Olympics athletes and coaches from multiple states

Record Currency Management Participates in Innovative European Bank for Reconstruction and Development (EBRD) -Backed Mongolian Tugrik Transaction19.6.2026 16:53:00 CEST | Press Release

Record Currency Management Ltd (RCM), subsidiary of London-listed Record plc (Record Financial Group), is pleased to announce its participation in an innovative local currency bond transaction issued by the European Bank for Reconstruction and Development (EBRD), supporting the development of Mongolia's capital markets while providing institutional investors with access to attractive frontier market opportunities. RCM is the UK currency management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. Headquartered in London, Record has offices in Hamburg, Zurich, Zug, New York, and Hong Kong. The investment forms part of Record Financial Group's broad

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press Release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level

Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press Release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press Release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye